Macular Degeneration

Anecortave acetate for fibrotic lesions with presence of residual peripheral activity in age-related
We retrospectively examined the efficacy of a single juxtascleral anecortave acetate depot injection for the treatment of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration in 20 consecutive patients who rejected intravitreal treatment.

Vienna, Austria
Austria
[Age-related macular degeneration.]
PURPOSE: Age-related macular degeneration is the commonest overall cause of irreversible blindness in patients aged 50 or over in the Western world.

Créteil, France 94010
France
Age-related macular degeneration: diagnosis and management
Background Age-related macular degeneration (AMD) is a leading cause of blind registration in Western Europe and the third leading cause of blindness worldwide.

London, UK
UK
Age-related macular degeneration: diagnosis and management
Background Age-related macular degeneration (AMD) is a leading cause of blind registration in Western Europe and the third leading cause of blindness worldwide.

London, UK
UK
Phacoemulsification does not induce neovascular age-related macular degeneration
PURPOSE: To investigate whether cataract surgery by phacoemulsification induces progression of early age-related macular degeneration (AMD) to neovascular AMD.

Recklinghausen,
Germany
Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-related Macular Degene
PURPOSE: To assess the efficacy and adverse-events profile of combined treatment with ranibizumab and verteporfin photodynamic therapy (PDT) in patients with predominantly classic choroidal neovascularization (CNV) secondary to neovascular age-related macular degeneration.

Charlotte, NC
USA
12-month retrospective study and review of photodynamic therapy with verteporfin for subfoveal choro
PURPOSE:: To evaluate the 12-month visual outcome of photodynamic therapy with verteporfin (PDT-V) for patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration and to verify the predictive role of visual and angiographic factors.

Naples, Italy, Ferrara, Italy, Campobasso, Italy
Italy
[Intravitreal anti-VEGF therapy with bevacizumab for neovascular AMD.]
PURPOSE: To report on the efficacy of intravitreal bevacizumab as off-label therapy in different angiographic subtypes in neovascular age-related macular degeneration (AMD).

Heidelberg, Germany
Germany
[Intravitreal administration of triamcinolone and bevacizumab for pigment epithelial detachment in c
BACKGROUND: The effect of the vascular endothelial growth factor (VEGF) inhibitors triamcinolone and bevacizumab (Avastin) on serous pigment epithelial detachment (PED) related to age-dependent macular degeneration (AMD) was analysed retrospectively.

Kiel, Germany
Germany
The temporal sequence of combined intravitreal triamcinolone acetonide and photodynamic therapy for
BACKGROUND AND OBJECTIVE: To compare visual acuity results in patients with exudative age-related macular degeneration treated with two different temporal sequences of combination intravitreal triamcinolone acetonide and photodynamic therapy with verteporfin.

New Brunswick, New Jersey
USA